![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
Ceplene® demonstrated a clinical interest in maintenance treatment of acute myeloid leukemia (AML) in patients below 60 years of age in first "complete remission" (symptom-free period of disease after initial treatment) in a clinical study.
Lead Product(s): Histamine Dihydrochloride,Interleukin 2
Therapeutic Area: Oncology Product Name: Ceplene
Highest Development Status: Phase IV Product Type: Small molecule
Recipient: Noventia Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 18, 2022